Tumori Journal is an international peer reviewed journal centred on cancer research and clinical practice in oncology, committed to providing authors with a swift review by our expert editorial board.
Tumori Journal aims to convey outstanding scientific reports covering all the facets of cancer science, and encourages submissions of original data of cancer biology and therapy, and application of new technologies for precision oncology, as well as randomized clinical trials. More specific subjects (i.e. radiotherapy, surgery, pathology) could be considered for publication only if they have particular relevance to the progression of oncology.
|Prof. Giancarlo Pruneri||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Luca Agnelli||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Giuseppe Aprile||Azienda ULSS 6 Vicenza, Italy|
|Dr. Fabrizio Bianchi||Fondazione IRCCS Casa Sollievo della Sofferenza, Italy|
|Dr. Andrea Billè||Guy's Hospital London, UK|
|Dr. Sergio Bracarda||Centro oncologico c/o PO S Donato, Italy|
|Dr. Cinzia Brunelli||Fondazione IRCCS Istituto Nazionale Tumori, Italy|
|Dr. Barbara Buldini||University of Padova School of Medicine and Surgery Padova Veneto Italy|
|Dr Daniele Cattaneo||Fondazione IRCCS Ca' Granda, Milan, Italy|
|Dr. Carlo Alfredo Clerici||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Michele Del Vecchio||Fondazione IRCCS Istituto Tumori, Milano|
|Dr. Serena Di Cosimo||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Massimo Di Maio||University of Turin, Italy|
|Dr. Lorenzo Ferrando||IRCCS Ospedale Policlinico San Martino, Genova, Italy|
|Andrea Ferrari MD||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Carlotta Galeone||Universita degli Studi di Milano, Italy|
|Dr. Patrizia Giannatempo||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Stefania Gori||Ospedale Sacro Cuore Don Calabria, Italy|
|Dr. Alessandro Gronchi||Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|
|Dr. Laura D Locati||Fondazione Salvatore Maugeri Istituto Scientifico, Pavia, Italy|
|Dr. Domenica Lorusso||Policlinico Universitario Agostino Gemelli, Rome|
|Dr. Monica Niger||Fondazione IRCCS Istituto Tumori, Milano|
|Dr. Ester Orlandi||Fondazione CNAO, National Center of Oncological Hadrotherapy, Italy|
|Dr. Fedro Peccatori||Istituto Europeo di Oncologia, Italy|
|Dr. Paola Perego||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr Giuseppe Procopio||Azienda Ospedaliera Socio Sanitaria Territoriale di Cremona, Italy|
|Dr. Paola Quarello||Regina Margherita Children's Hospital Turin Piemonte, Italy|
|Dr Mario Silva||University of Parma, Italy|
|Dr. Antonio Silvani||Fondazione IRCCS Carlo Besta, Milan, Italy|
|Dr. Carlo Sposito||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Elena Tamborini||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Annalisa Trama||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Andrea Vingiani||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
|Dr. Gabriele Zoppoli||Università di Genova, Italy|
|Dr. Matti S. Aapro||Clinique de Genolier, Switzerland|
|Dr Stefan Aebi||Luzerner Kantonsspital, Switzerland|
|Dr. Joachim Aerts||Amphia Ziekenhuis, Netherlands|
|Dr. Emiliano Calvo||START Madrid Centro Integral Oncologico Clara Campal, Spain|
|Dr. Wanqing Chen||National Cancer Center, China|
|Dr. Joachim Cohen||Vrije Universiteit Brussel, Belgium|
|Dr. Padraig D'Arcy||Linkopings universitet, Sweden|
|Dr. Maria De Santis||University of Warwick, UK|
|Dr. Simon Ekman||Uppsala University Hospital, Sweden|
|Professor Alexandre Escargueil||Centre de Recherche Saint-Antoine, France|
|Dr. Rui Henrique||Portouguese Oncology Institute-Porto, Portugal|
|Dr. Kenzo Hiroshima||Yachiyo Medical Center, Japan|
|Dr. Carmen Jerónimo||Portoguese Oncology Institute of Porto, Portugal|
|Dr. Natasha Leighl||University of Toronto, Canada|
|Dr. Herbert H. Loong||Department of Clinical Oncology and Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong|
|Dr. Cynthia A. Mapua||St Luke's Medical Centerl, Philippines|
|Dr. Tomohiro Matsuda||National Cancer Registry Center, Japan|
|Dr. Mari Mino-Kenudson||Massachusetts General Hospital, USA|
|Dr. Andre L Moreira||NYU Langone Medical Center, USA|
|Dr. Yukio Nakatani||University Graduate School of Medicine, Japan|
|Dr. Tom Newsom-Davis||Chelsea and Westminster Hospital, UK|
|Dr. Chang-Mo Oh||Kyung Hee University, Republic of Korea|
|Dr. Christoph Ostgathe||Cancer Center Erlangen, Germany|
|Dr. Luis Paz-Arez||Hospital Universitario Doce de Octubre, Universidad Complutense and CNIO, Spain|
|Dr. Martin Reck||LungenClinic Grosshansdorf, Germany|
|Dr. Satoru Sagae||JR Sapporo Hospital, Japan|
|Dr. Hutcha Sriplung||Prince of Songkla University, Thailand|
|Dr. Elena Colombo||Fondazione IRCCS Istituto Nazionale dei Tumori, Italy|
Manuscript Submission Guidelines: Tumori Journal
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/tmj to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Tumori Journal will be reviewed.
There are no fees payable to submit or publish in this Journal. Open Access options are available - see section 3.4 below.
As part of the submission process you will be required to include a Research in Context paper for us to understand how your manuscript would improve general knowledge and add value to the research topic. This should be no more than 500 words / 3,500 characters. We hope that this format helps our readers to identify more quickly the breakthrough aspect of your study.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that Tumori Journal will consider submissions of papers that have been posted on preprint servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the Journal. If the article is accepted for publication, the author may re-use their work according to the Journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.
2.1 Peer review policy
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
Before submitting your manuscript to Tumori Journal, please ensure you have read the Aims & Scope.
Original research articles
Previously unpublished manuscripts, describing clinical, pre-clinical, epidemiological investigations, clinical trials, clinical observations, and other relevant investigations that are based on sound patient series, validated analytical methods, and appropriate statistical evaluation.
Original research articles should be structured as follows: Introduction (clearly stating an objective or hypothesis), Methods (describing the study design and methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria, and/or participation or response rates, or data sources, and how these were selected for the study), Results (describing the results of the study in context with the published literature and addressing study limitations), and Discussion (addressing relevant implications for clinical practice or health policy). A structured abstract is required.
Tumori Journal encourages authors to submit a visual abstract alongside their original research manuscript. The file for the visual abstract should be uploaded as supplemental material when submitting a paper. Authors may use their own template or either of the templates provided here: TMJ_Visual Abstract Template 1 and here: TMJ_Visual Abstract Template 2.
The visual abstract should promote the content of the article by providing the reader with a quick understanding of its take-home of message and the research area on which the study focuses. The visual abstract encourages dissemination and sharing of the article through social media by fostering scientific debate.
Visual abstracts submitted alongside the manuscript will be subject to peer review.
Words: max 3000 (excluding figures and tables)
Figures/Tables: max 6
References: max 50
Clinical trial protocols
A clinical trial is defined as any research project that prospectively assigns human participants to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. Each manuscript should be divided as follows: Introduction (stating an objective or hypothesis of the protocols), Methods (describing the design and statistical methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria), Results (including data on recruitment, etc.), and Discussion (placing the protocol in context with the published literature). A structured abstract is required, and trial registration information (name, number, and URL) must be listed in the title page.
Words: max 3000 (excluding figures and tables)
Figures/Tables: max 6
References: max 50
Reviews are solicited by the Editor in Chief on topics that are deemed to be relevant to the audience of the Journal. Containing the current state of knowledge or practice, integrating recent advances with accepted principles and practice, or summarizing and analyzing consensus view of controversial issues in knowledge of practice. A non-structured abstract is required.
Words: max 5000 (excluding figures and tables)
Figures/Tables: max 8
References: no limit
Editorials (Invitation only)
The purpose of the editorials is to provide the reader with a balanced overview of relevant and up to date subjects concerning the Journal's aim or future direction. A non-structured abstract is required.
Words: max 4000 (excluding figures and tables)
Figures/Tables: max 8
References: No limit
This article type reports of results from original researches. They must provide conclusive findings: preliminary observations or incomplete findings cannot be considered for publication. A non-structured abstract is required.
Words: max 2000 (excluding figures and tables)
Figures/Tables: max 4
References: max 20
Case reports (Published online only)
Case reports will be accepted if they describe a previously undescribed clinical case and are of very high importance for dissemination. Case reports will be published online only in a dedicated issue. Case reports must be structured as follows: Introduction (explaining the importance of the case), Case Description (providing all relevant information), and Conclusions (describing the detailed outcome of the report). A structured abstract is required.
Words: max 2000 (excluding figures and tables)
Figures/Tables: max 3
References: max 10
Letters to the Editor are intended to present opinions or comments on articles published in the Journal. Letters are subject to abridgement and editing for style and content. An abstract is not required.
If you are the corresponding author of an article cited in a Letter to the Editor and receive an email invitation to comment on it, you must log in to the system, accept the invitation immediately, and then upload and submit your reply to the Editorial Office. The response must cite the title of the letter, e.g., “Response to (Title of Letter)”.
Words: max 500 (excluding figures and tables)
References: max 5
The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online
Manuscripts that do not adhere to the guidelines for submission will be returned to the corresponding author for technical revision before undergoing the peer review process. Manuscripts with insufficient priority for publication will be rejected promptly.
Peer review is the process we use to assess the quality of a manuscript to see if it suitable for publication. Independent researchers with similar competencies assess submitted manuscripts for originality, validity and importance to help our Editors determine if a manuscript is suitable for publication in their journal.
We utilise a single-blind peer-review system, which is considered to be self-regulating. Reviewers are aware of the names and affiliations of the authors, but the reviewer assessments provided to authors are completely anonymous. The single-blind peer review system is the most commonly-used method of review and most Reviewers are comfortable with this approach, as it facilitates an impartial appraisal of a manuscript.
Submitted manuscripts are reviewed by two or more referees who evaluate whether the manuscript is scientifically logical and well-constructed, focussing specifically on if it duplicates previously published work, and if there are clear grounds for it to be considered for publication. The Editors establish their decision based on these reports and, if necessary, they can discuss with members of the Editorial Board.
We aim to provide authors with a first decision (of accept, reject or revisions required whether minor or major) within 4 weeks.
All correspondence related to the submission, including editorial decisions, will be sent by email to the corresponding author. In case of revision, detailed revision instructions will be sent and a point-by-point response will be required. The Journal does not reveal the identity of its reviewers.
Authors can check the status of their manuscript at any time by logging into the journal's submission system, ScholarOne.
Appeals and complaints
If you would like to appeal a rejection decision or make a complaint, please contact the Publisher who will outline the journal's complaints procedure.
As part of the submission process you will be asked to provide the name of a minimum of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
2.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Tumori Journal requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Tumori Journal to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. . Experimental research performed on animals must comply with the NIH Guide for the Care and Use of Laboratory Animals or equivalent. A statement that research has been performed according to the NIH Guidelines must be included in the Methods section.
Tumori Journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway
Tumori Journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
If material has been previously published it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Sage’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants Sage the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than Sage. In this case copyright in the work will be assigned from the author to the society. For more information please visit the Sage Author Gateway.
There is no charge for publishing in Tumori Journal for articles or other contributions equal to or less than 4,000 words. For any contribution over 4,000 words a publication charge of £300 (plus VAT where applicable) to support the costs of dissemination will apply. The 4,000 word limit includes the title, abstract, keywords, main article, tables, declarations, any acknowledgments or notes, and references.
Sage may choose to publish selected articles prior to payment; however publication of the accepted article does not constitute waiving of the charge. Sage reserves the right to refuse future submissions if there are outstanding payments due.
An invoice will be sent to your nominated billing address. Payment terms are 30 days from the invoice date.
Tumori Journal offers optional open access publishing via the Sage Choice programme and Open Access agreements, where authors can publish open access either discounted or free of charge depending on the agreement with Sage. Find out if your institution is participating by visiting Open Access Agreements at Sage. For more information on Open Access publishing options at Sage please visit Sage Open Access. For information on funding body compliance, and depositing your article in repositories, please visit Sage’s Author Archiving and Re-Use Guidelines and Publishing Policies.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines
Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from Sage after receipt of your accepted article.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.
Tumori Journal is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts (https://mc.manuscriptcentral.com/tmj). For further guidance on submitting your manuscript online please visit http://mchelp.manuscriptcentral.com/gethelpnow/
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.
As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway
Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite Online First articles.
Sage provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to Tumori Journal editorial office as follows: email@example.com